Fluconazole

Catalog No.S1331 Batch:S133103

Print

Technical Data

Formula

C13H12F2N6O
Molecular Weight 306.27 CAS No. 86386-73-4
Solubility (25°C)* In vitro DMSO 61 mg/mL (199.17 mM)
Ethanol 61 mg/mL (199.17 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Fluconazole is a fungal lanosterol 14 alpha-demethylase inhibitor, which thereby prevents the formation of ergosterol, used in the treatment and prevention of superficial and systemic fungal infections.
Targets
lanosterol 14 alpha-demethylase [1]
In vitro

Fluconazole in combination with amphotericin B (AmB) has a synergistic effect on C. albicans planktonic cells but does not alter AmB activity against biofilms. This compound and caspofungin have an antagonistic effect against biofilms but not with planktonic cells. It-mediated membrane perturbation (due to inhibition of ergosterol biosynthesis) increases calcineurin inhibitor intracellular concentrations. This treatment significantly reduces levels of ergosterol within the cell in C. albicans planktonic cells, leading to cell membrane perturbation. Its activity is less sensitive to acidic medium than is that of ketoconazole. The compound is approximately 16-fold less active than ketoconazole against 35 representative isolates of C. albicans at physiologic pH. Fluvastatin, a cholesterol-lowering drug, exhibits minimal activity (MICs of 64 to >128 mg/mL) against Candida species and Cryptococcus neoformans. This chemical combined with itraconazole exhibits potent activities against C. albicans, C. tropicalis, C. parapsilosis, and C. neoformans, including flucon- azole-resistant strains of C. albicans and C. tropicalis.

In vivo

Fluconazole is very effective in prolonging survival of rats infected with a representative candidal strain. This compound has a dramatic effect on the fungicidal activity of flucytosine in murine cryptococcal meningitis. It combined with flucytosine and amphotericin B have significantly improved activity against cryptococcal meningitis compared with the activity of each drug used alone.

Protocol (from reference)

References

  • https://pubmed.ncbi.nlm.nih.gov/18180354/
  • https://pubmed.ncbi.nlm.nih.gov/3022641/
  • https://pubmed.ncbi.nlm.nih.gov/9087504/
  • https://pubmed.ncbi.nlm.nih.gov/8878602/

Selleck's Fluconazole Has Been Cited by 33 Publications

Terconazole, an Azole Antifungal Drug, Increases Cytotoxicity in Antimitotic Drug-Treated Resistant Cancer Cells with Substrate-Specific P-gp Inhibitory Activity [ International Journal of Molecular Sciences, November 09, 2022, 13809] PubMed: 36430288
Peroxin Pex8 couples stress responses, antifungal tolerance, and virulence regulation in Candida albicans [ Antimicrobial Agents and Chemotherapy, March 24, 2025, e01662-25] PubMed: 41874383
In vitro interactions of proton pump inhibitors and azoles against pathogenic fungi [ Frontiers in Cellular and Infection Microbiology, January 17, 2024, 1296151] PubMed: 38304196
CO2 potentiates echinocandin efficacy during invasive candidiasis therapy via dephosphorylation of Hsp90 by Ptc2 in condensates [ Proceedings of the National Academy of Sciences, February 11, 2025, e2417721122]
Pyrvinium Pamoate Synergizes with Azoles in vitro and in vivo to Exert Antifungal Efficacy Against Candida auris and Other Candida Species [ Infection and Drug Resistance, February 10, 2025, 783-789]
Rad6 and Bre1 ubiquitin ligase negatively regulate biofilm formation and virulence in Candida glabrata [ J Infect, 2025, 91(3):106595] PubMed: 40850399
Adaptive morphological changes link to poor clinical outcomes by conferring echinocandin tolerance in Candida tropicalis [ PLoS Pathog, 2025, 21(5):e1013220] PubMed: 40424325
Osh2 mediates Candida species resistance to miltefosine by regulating zymosterol accumulation [ Antimicrob Agents Chemother, 2025, 69(9):e0042725] PubMed: 40698822
Pyrvinium Pamoate Synergizes with Azoles in vitro and in vivo to Exert Antifungal Efficacy Against Candida auris and Other Candida Species [ Infect Drug Resist, 2025, 18:783-789] PubMed: 39958982
In vitro interactions of proton pump inhibitors and azoles against pathogenic fungi [ Front Cell Infect Microbiol, 2024, 14:1296151] PubMed: 38304196

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.